Lodo Therapeutics has achieved a second preclinical milestone in its multi-target strategic collaboration with Genentech, a member of the Roche Group. Lodo Therapeutics is using its proprietary genome mining and biosynthetic gene cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.
Under the terms of the agreement, Lodo is eligible to receive research, development and commercialization payments based on achievement of certain predetermined milestones. In addition, Lodo received an undisclosed upfront payment and is eligible to receive royalties on sales of certain products resulting from the collaboration.
"Our collaboration with Genentech has now achieved a second preclinical milestone, and we anticipate additional milestones in the months ahead," said Dale Pfost, PhD, Chairman and CEO of Lodo Therapeutics. "Genentech has been an excellent partner as we have expanded the capabilities of our P4 discovery platform, and we look forward to furthering our mutually productive relationship."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Lodo's DNA-first approach identifies promising bioactive molecules directly from sequence data encoded in biosynthetic gene clusters (BGCs) in microbial DNA. By hacking into nature's BGCs, Lodo is leveraging evolution-driven chemical diversity and biological relevance to identify novel drugs for hard-to-treat disease targets.